A Clinical Urine Metabolomics Dataset for Urological Malignancies

ABSTRACT: Renal cell carcinoma, bladder cancer, and prostate cancer rank among the most common urological malignancies, yet clinically satisfactory non-invasive screening tools for these cancers are still lacking. Here we present an untargeted urine metabolomics dataset generated by liquid chromatography coupled with high-resolution mass spectrometry from 368 clinical urine samples, comprising 249 patients with urological malignancies (194 renal cancer, 39 bladder cancer, and 16 prostate cancer), 62 patients with benign renal , and 57 healthy controls. Clear cell renal cell carcinoma (ccRCC) was the dominant histological subtype in the renal cancer subgroup (170 cases, 87.6%). Chromatographic separation was carried out on an ACQUITY UPLC I-Class system, and detection was performed on a Q Exactive Orbitrap high-resolution mass spectrometer in both positive and negative electrospray ionization modes. Raw data were processed through peak detection, baseline correction, alignment, annotation, and a multi-step normalization pipeline, yielding a final set of 472 metabolic features common to all three groups. The full dataset, along with clinical metadata, data processing scripts, and heatmap visualization code, has been deposited on figshare to support urinary biomarker discovery, diagnostic modeling, and metabolic pathway investigation in urological oncology.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse-phase, Liquid Chromatography MS - positive - reverse-phase

PROVIDER: MTBLS14865 | MetaboLights | 2026-06-27

REPOSITORIES: MetaboLights